Discover
MLYS
Mineralys Therapeutics, Inc.
27.19
1 x 27.17
1 x 27.21
bid
ask
-
0.19
0.70%
12:33 PM
timesize
| Ytd | -25.08% | |
| 1y | 106.13% |
26.71
day range
27.57
12.59
52 week range
47.65
| Open | 27.20 | Prev Close | 27.38 | Low | 26.71 | High | 27.57 | Mkt Cap | 2.40B |
| Vol | 208.08K | Avg Vol | 1.40M | EPS | -2.05 | P/E | -13.26 | Forward P/E | -13.05 |
| Beta | 0.68 | Short Ratio | 6.07 | Inst. Own | 109.75% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-06 | 50-d Avg | 26.62 | 200-d Avg | 31.03 | 1yr Est | 49.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-12 | 2026-06 | -0.55 | N/A | N/A | N/A |
| 2026-05-06 | 2026-03 | -0.51 | -0.47 | 0.04 | 7.84% |
| 2026-03-12 | 2025-12 | -0.52 | -0.4 | 0.12 | 22.52% |
| 2025-11-10 | 2025-09 | -0.66 | -0.52 | 0.14 | 21.21% |
| 2025-08-12 | 2025-06 | -0.78 | -0.66 | 0.12 | 15.38% |
| 2025-05-12 | 2025-03 | -1.02 | -0.79 | 0.23 | 22.55% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-04-27 | TD Cowen | Upgrade | Buy | |
| 2026-03-13 | B of A Securities | Upgrade | Buy | Buy |
| 2025-12-19 | Stifel | Upgrade | Buy | Buy |
| 2025-11-12 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2025-11-11 | Wells Fargo | Upgrade | Overweight | Overweight |
| 2025-10-30 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-02-18 | AKKARAJU SRINIVAS | Director and Beneficial Owner of more than 10% of a Class of Security | 5.88M | Stock Award(Grant) |
| 2026-07-12 | CONGLETON JON | Chief Executive Officer | 603.62K | Sale |
| 2026-06-16 | KARYDAS DAPHNE | Director | 6.20K | Conversion of Exercise of derivative security |
| 2026-02-18 | LEVY ADAM SCOTT | Chief Financial Officer | 48.54K | Stock Award(Grant) |
| 2026-03-29 | RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2026-07-16 | RODMAN DAVID MALCOM | Officer | 51.38K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Catalys Pacific, LLC | 7.90M | 216.17M | 9.58% |
| 2026-03-30 | RA Capital Management, L.P. | 7.69M | 210.40M | 9.32% |
| 2026-06-29 | Blackrock Inc. | 5.89M | 161.01M | 7.14% |
| 2026-03-30 | Samsara BioCapital, LLC | 5.87M | 160.57M | 7.12% |
| 2026-03-30 | FMR, LLC | 4.86M | 132.95M | 5.89% |
| 2026-06-29 | State Street Corporation | 4.14M | 113.27M | 5.02% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.81M | 76.86M | 3.41% |
| 2026-04-29 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.86M | 50.83M | 2.25% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.77M | 48.53M | 2.15% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 1.50M | 41.14M | 1.82% |
| 2026-06-29 | Fidelity Select Portfolios-Select Health Care Portfolio | 1.18M | 32.27M | 1.43% |
| 2026-06-29 | American Century Mutual Funds, Inc.-Small Cap Growth Fund | 792.38K | 21.67M | 0.96% |